Navigation Links
Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Date:7/6/2008

atients with advanced NSCLC were randomized to the comparator arm; 191 were randomized to the OPAXIO arm with a dosage of 175 mg/m^2, and 96 were randomized to the OPAXIO arm at a dosage of 235 mg/m^2. The OPAXIO dose was reduced to 175 mg/m^2 after 96 patients had been treated, because the Data Monitoring Committee noted an increase in deaths associated with neutropenia in patients who had received the 235 mg/m^2 dosage. The following data refers to those patients treated at the OPAXIO dose of 175 mg/m^2. The median number of cycles administered was 4, with a median of 3.5 in the control arm. A total of 754 cycles of OPAXIO were administered, and 652 cycles were administered in the comparator arm. More patients in the OPAXIO arm received 6 cycles of treatment (38 percent versus 23 percent; p = 0.002). Progressive disease was the most common reason for not completing 6 cycles (55 percent in the OPAXIO arm and 59 percent in the comparator arm). Fewer OPAXIO patients (12 percent) discontinued treatment as a result of adverse events, compared to 17 percent of patients in the control arm. Survival, time to progression (TTP), and response rates were similar in both arms. Median overall survival was 7.3 months in the OPAXIO arm and 6.6 months in the control arm. The estimated 1-year survival rate was the same in both arms (26 percent), and the approximate 2-year survival rate was numerically higher in the OPAXIO arm (15 percent) than the comparator arm (10 percent). There was a lower requirement for red blood cell transfusions (p = 0.001), erythropoietin use (p = 0.014), myeloid growth factors (p = 0.032), and new narcotic analgesics (p = 0.034) in the OPAXIO arm when compared to the control arm. No significant differences were evident in quality of life based on FACT-LCS evaluations between the two arms. OPAXIO patients experienced fewer hematologic (p <0.001) and gastrointestinal (p = 0.004) adverse events. Neuropathy occurred more frequently in the OPAXIO arm compared
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
2. Genzyme and Isis Complete Licensing of Mipomersen
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
10. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
11. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today announced ... (the generic equivalent of Zyprexa® injection), in Canada.  Olanzapine ... disturbed behaviors in patients with schizophrenia or bipolar I ... injectable drug, InnoPharma has entered into an agreement with ... will make, use, sell, market and distribute Olanzapine ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... and NYSE: SNY ) today announced that ... people with hypercholesterolemia met their primary efficacy endpoint of ... cholesterol (LDL-C) at 24 weeks compared to placebo or ... PCSK9 (proprotein convertase subtilisin/kexin type 9). In ...
Breaking Medicine Technology:Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... New data being presented at the American College ... San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) ... in a statistically significant greater percentage of nights ... disease (GERD), compared to placebo (p<0.001). In addition, ...
... SAN DIEGO, Oct. 26 Volcano Corporation (Nasdaq: VOLC ... products for the diagnosis and treatment of coronary and peripheral ... results for the third quarter and first nine months of ... hold a conference call to discuss its financial results and ...
Cached Medicine Technology:New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD 2New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD 3Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2
(Date:7/30/2014)... as evolutionary changes in a living organismhad been thought ... genome. , However, recent studies have shown that cancer ... arise simultaneously and in close proximity to each other. ... regions where chromosomal rearrangements take place. , The discovery, ... one day lead to new cancer therapies, according to ...
(Date:7/30/2014)... News) -- Some obese people have a genetic mutation ... their brains when they see food, researchers report. ... feelings of pleasure and gratification at the sight of ... to prevent overeating, the scientists suggested. More than ... typically caused by a combination of overeating, a lack ...
(Date:7/30/2014)... Georgia (PRWEB) July 30, 2014 The ... and Technology Alliance of TAG (B&TA), today issued its ... TAG Excalibur Awards. , Interested companies have until August ... after which, Semi-Finalists will be selected by the Excalibur ... required to meet with the judges for interviewing process. ...
(Date:7/30/2014)... 30, 2014 The American Telemedicine ... Sens. Thad Cochran (R-MS) and Roger Wicker (R-MS) ... telemedicine coverage under Medicare, Medicaid and Federal Communications ... Mississippi Republicans, introduced the Telehealth Enhancement Act as ... version, H.R. 3306, introduced by Rep. Gregg Harper ...
(Date:7/30/2014)... 2014 2014 Deep Research ... is a professional and in-depth research report ... provides basic Chitosan information, including Chitosan definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Gene Mutation May Make Food More Tempting 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4
... 14 ECRI Institute Patient Safety Organization (PSO) ... Coalition for Quality & Patient Safety (CQPS) of ... reporting, and analysis. The Chicagoland PSO focuses on ... specific to Chicago and the surrounding counties. CQPS ...
... 14 May 2009 Research4Life today announces that ... (OARE) program has registered 1500 institutions since its ... percent. This means that scientists, researchers and environmental ... poorest countries can gain free or low cost ...
... Anpath Group, Inc. (OTC Bulleting Board: ANPG), ... (ESI) and its distributor partner, Minntech Japan Corporation, ... 36th annual meeting of the Japanese Society of ... meeting was attended by over 4,000 medical professionals. ...
... Research Month activities include spring dedication at the ... Today Intergraph(R) and the Huntsville Botanical Garden once ... at the Intergraph Garden of Hope spring dedication. ... from the Huntsville community convened to celebrate life ...
... Stem for Life FoundationNEW YORK, May 14 NeoStem, Inc. ... pre-disease collection, processing and long-term storage of adult stem cells ... agreement for Ceres Living, Inc., a developer and direct marketer ... of an innovative nutritional supplement - AIO Premium Cellular Health. ...
... GABLES, Fla., May 14 Catalyst Pharmaceutical Partners, Inc. (Nasdaq: ... first quarter ended March 31, 2009. First Quarter ... the Company reported a net loss of $3,031,201, or $0.22 ... of $1,584,047, or $0.13 per basic and diluted share, for ...
Cached Medicine News:Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 2Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 3Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 4Health News:Coalition for Quality & Patient Safety of Chicagoland PSO Taps ECRI Institute PSO for Patient Safety Support 5Health News:Access to environmental research in developing nations grown to 1,500 institutions 2Health News:Anpath Group, Inc. Distributor Introduces Products at the Japanese Society of Intensive Care Medicine Annual Meeting 2Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 2Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 3Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 4Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 5Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 6Health News:Courageous Cancer Survivors Honored at Intergraph(R) Garden of Hope 7Health News:NeoStem Signs Agreement for Ceres Living, Inc. to Market Innovative Nutritional Supplement Designed to Optimize Stem Cell Functions 2Health News:NeoStem Signs Agreement for Ceres Living, Inc. to Market Innovative Nutritional Supplement Designed to Optimize Stem Cell Functions 3Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 2Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 3Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 4Health News:Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results 5
... The new SureCut M3500 Radial Microtome has ... is marvelous, and a range of functions and ... users. Based on years of experience and ... innovative design the SureCut M3500 Microtome will be ...
Spare fuse set...
Clock oil, 6 grams net...
Honing compound for knife sharpening, 6 grams net...
Medicine Products: